DekaBank Deutsche Girozentrale’s Ocular Therapeutix OCUL Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$1.01M	–	1283
2025 Q4	$1.01M	Hold	100,000	–	–	﹤0.01%	876
2025 Q3	$1.24M	Hold	100,000	–	–	﹤0.01%	835
2025 Q2	$918K	Hold	100,000	–	–	﹤0.01%	883
2025 Q1	$746K	Hold	100,000	–	–	﹤0.01%	892
2024 Q4	$828K	Hold	100,000	–	–	﹤0.01%	905
2024 Q3	$857K	Hold	100,000	–	–	﹤0.01%	919
2024 Q2	$669K	Hold	100,000	–	–	﹤0.01%	955
2024 Q1	$892K	Hold	100,000	–	–	﹤0.01%	898
2023 Q4	$461K	Hold	100,000	–	–	﹤0.01%	1056
2023 Q3	$313K	Hold	100,000	–	–	﹤0.01%	1120
2023 Q2	$505K	Buy	100,000 +75,000	+300%	+$446K	﹤0.01%	1022
2023 Q1	$137K	Buy	+25,000	New	+$119K	﹤0.01%	1230
2021 Q4	–	Sell	-22,900	Closed	-$230K	–	1460
2021 Q3	$230K	Hold	22,900	–	–	﹤0.01%	1182
2021 Q2	$312K	Hold	22,900	–	–	﹤0.01%	1138
2021 Q1	$361K	Hold	22,900	–	–	﹤0.01%	1078
2020 Q4	$454K	Buy	+22,900	New	+$340K	﹤0.01%	1041
2016 Q2	–	Sell	-10,000	Closed	-$94K	–	1027
2016 Q1	$94K	Buy	+10,000	New	+$75.7K	﹤0.01%	969

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DekaBank Deutsche Girozentrale's OCUL Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 100,000 shares — an estimated $1.01M sold.

DekaBank Deutsche Girozentrale first reported a position in OCUL in Q1 2016 and held it in 17 quarters. The position peaked at $1.24M in Q3 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 100,000 Ocular Therapeutix shares in Q1 2026, an estimated $1.01M.
DekaBank Deutsche Girozentrale first reported a position in Ocular Therapeutix in Q1 2016 and held it in 17 quarters.
DekaBank Deutsche Girozentrale's Ocular Therapeutix position peaked at $1.24M in Q3 2025.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.